Featured Insights

Insights

<>

October 10, 2016

Talk at the Top Podcast

Roger Longman on the Drug Pricing War

Roger Longman speaks about drug pricing in the current environment, and how payers, pharma, and providers must adapt to ever-changing models of reimbursement.

Listen to the full insight interview >

July 18, 2016

In Vivo

The Value Lab: Moving Value-Based Health Care from Theory to Practice

A new, structured approach to bringing value-based reimbursement models into the mainstream is outlined, thus transforming reimbursement and fueling the shift from volume to value.

Read full insight article >

January 13, 2016

NEJM Catalyst

Who Has the Power to Cut Drug Prices?

Employers have the greatest potential to influence drug prices by being much more aggressive in getting PBMs and payers to have skin in the drug-pricing game.

Read full insight article >

January 1, 2016

Ernst & Young

The “Myth” of the Payer

Not all payers make their decisions the same way. Smart payer segmentation strategies are extremely important to successful biopharmas.

Read full insight article >

December 1, 2015

Harvard Business Review

Who Has the Power to Cut Drug Prices? Employers.

Employers have the greatest potential to influence drug prices by being much more aggressive in getting PBMs and payers to have skin in the drug-pricing game.

Read full insight article >

November 12, 2015

Journal of Clinical Pathways Viewpoints

Overcoming the Political and Economic Roadblocks Stopping Effective Comparative Drug Evaluation

Transparent comparative evaluations are necessary for determining the relative value of drugs. But, in part because of resistance from drug companies and payers, stakeholders are finding other tools to help identify the appropriate choices.

Read full insight article >